.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The CRASH-2 randomized trial evaluated tranexamic acid in adults with significant traumatic bleeding or risk of significant bleeding. The study addressed a high-stakes surgical and trauma question: can an inexpensive antifibrinolytic reduce mortality when administered early after injury? The trial demonstrated a reduction in death due to bleeding among patients receiving tranexamic acid, with the greatest benefit associated with earlier treatment. The results helped establish tranexamic acid as a major component of modern trauma resuscitation pathways. For surgeons and trauma teams, the important lesson is timing. A therapy with a favourable evidence profile may lose benefit when treatment is delayed, making early recognition and protocolized administration crucial. CRASH-2 also illustrates how large pragmatic trials can rapidly change practice across very different healthcare settings. The clinical role of tranexamic acid still requires appropriate patient selection and integration into broader haemorrhage control. It does not replace definitive management of bleeding, damage-control surgery, transfusion support or correction of physiologic derangement. For ASICON's trauma training emphasis, CRASH-2 remains a useful evidence anchor: early, simple interventions can have major effects when incorporated into systematic trauma care.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The CRASH-2 randomized trial evaluated tranexamic acid in adults with significant traumatic bleeding or risk of significant bleeding. The study addressed a high-stakes surgical and trauma question: can an inexpensive antifibrinolytic reduce mortality when administered early after injury? The trial demonstrated a reduction in death due to bleeding among patients receiving tranexamic acid, with the greatest benefit associated with earlier treatment. The results helped establish tranexamic acid as a major component of modern trauma resuscitation pathways. For surgeons and trauma teams, the important lesson is timing. A therapy with a favourable evidence profile may lose benefit when treatment is delayed, making early recognition and protocolized administration crucial. CRASH-2 also illustrates how large pragmatic trials can rapidly change practice across very different healthcare settings. The clinical role of tranexamic acid still requires appropriate patient selection and integration into broader haemorrhage control. It does not replace definitive management of bleeding, damage-control surgery, transfusion support or correction of physiologic derangement. For ASICON's trauma training emphasis, CRASH-2 remains a useful evidence anchor: early, simple interventions can have major effects when incorporated into systematic trauma care.
Yesterday
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
